Deal inked in October 2007 has a potential value of over $1 billion.
Galapagos received multiple €3.75 million, or $4.92 million, under its alliance with Janssen for rheumatoid arthritis therapeutics. The milestones are a result of preclinical proof-of-principle studies for compounds developed against Galapagos targets.
The compounds demonstrated a reduction of an inflammatory disease biomarker in inflamed joint tissue cultured from collagen-induced arthritic mice.
In January 2008, Galapagos received its first milestone fee of E3.4 million. Galapagos obtained E15 million as an up-front payment in a deal that could be worth over $1 billion. Janssen gained rights to acquire small molecules from up to 12 of Galapagos’ internal programs involving rheumatoid arthritis therapeutic targets.
—
